Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
about
High resolution melting for mutation scanning of TP53 exons 5-8Ovarian carcinoma subtypes are different diseases: implications for biomarker studiesRecent concepts of ovarian carcinogenesis: type I and type IIDNA methylation changes in epithelial ovarian cancer histotypes.Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification.Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors.cDNA sequencing improves the detection of P53 missense mutations in colorectal cancerMicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.Frequent downregulation of miR-34 family in human ovarian cancers.Association of myeloperoxidase with ovarian cancer.Frequent MAGE mutations in human melanomaOvarian cancer: pathology, biology, and disease modelsNuclear envelope structural defects cause chromosomal numerical instability and aneuploidy in ovarian cancer.Asparagine synthetase: a new potential biomarker in ovarian cancer.Ovarian cancer development and metastasis.Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.Differential analysis of ovarian and endometrial cancers identifies a methylator phenotypeRecent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube.The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations.Discovery of prognostic factors for diagnosis and treatment of epithelial-derived ovarian cancer from laying hens.VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancerDerivation and characterization of matched cell lines from primary and recurrent serous ovarian cancerZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survivalDistinct gene expression profiles in ovarian cancer linked to Lynch syndromeAdenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms.Fallopian tube origin of supposed ovarian high-grade serous carcinomas.Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinomaRisk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutationsSurvival in women with grade 1 serous ovarian carcinomaHereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problemsFirst in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma.Small-molecule inhibitor of Bcl-2 (TW-37) suppresses growth and enhances cisplatin-induced apoptosis in ovarian cancer cells.Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome.Prognostic role of CIP2A expression in serous ovarian cancerBevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancerMutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells.
P2860
Q21260416-36920BAF-61DA-401A-90CF-95E658F49027Q21563402-8482325D-87A3-4D63-B212-CC826D9F969CQ27009487-65AE3571-AA88-4C89-94C1-CF4571F3002CQ27690722-B865C0E1-CF9D-4348-88DD-6D2B856724C9Q27851709-BA58E44B-D208-4C68-B36F-451C77C942A6Q31141440-1466C641-C18F-4094-B531-97055DD7EF5FQ33308740-22206C9A-D779-4DF4-A9A1-2AFC6E7798FEQ33387074-53EA4ECD-04EC-4AEF-8BD7-03194D39EA00Q33492556-FD535051-1BF9-47D5-8857-18B2DB73F091Q33508232-D06E5E65-08E3-4E91-BFC0-929C612C2E79Q33658229-13A1B4E4-DE62-42DC-8C40-5762BA64A2F8Q33689246-28409531-0E35-4EFB-B6F1-194787C3A4C8Q33700477-B81DC911-6CDF-4FA0-9CDC-9E896ACFCCF2Q33807748-7EA53907-E62B-4CBA-AE5B-F2A553D9CCF2Q33856490-E34AD65D-4101-4217-B4BA-FEBEB053FECBQ33894413-6E35D50F-CE7C-4929-B5FF-9A2831EF9086Q34086819-C2A2FC08-ACE4-4B11-9AF1-0628233B1F60Q34097804-0DBA5DA6-5C8A-4061-95EA-9E41DC1C56AEQ34162272-82212129-16CD-4A81-A2E4-2BD5B8A19043Q34189765-0C602EF1-721A-4735-A467-786A3C5FCF39Q34201837-C4DF69C3-CDF4-4F93-912F-F014E27B1AF3Q34288214-8D5EB503-9B1A-4712-A787-5BABF01C7221Q34305434-DFF216D8-FE70-4AAF-87CE-FA0FDCFC26EFQ34328133-A1201006-3918-45F0-944C-3B4FD43C1AECQ34397197-F43AC297-AAE4-4775-A893-DB5897701CCDQ34431079-41A00A7D-A632-4AA4-A4EC-98C3876D43A8Q34507528-A8F88F0D-451A-424B-B90D-E80C18D1859FQ34528553-A68C2D71-3CFE-4419-855D-78BC2F878931Q34604042-1A23D781-AAB8-4461-BABF-6F09ABDE1C7BQ34626854-66FF0CA5-F666-4D74-82F3-74C0B3C4933EQ34811314-23CA1914-F01C-4C53-ACFE-8A66565138B0Q34967339-64FA64FB-0822-439E-A5BD-BF7765E7D78CQ34977063-1C543800-FCA6-4579-A8FC-70EF6B9C5C8CQ34998994-BCC375E2-9F2B-409A-B9CC-D67349F506F2Q35110920-4157F0FB-04BE-42EA-AB0D-864EA38E55EBQ35154341-344F928A-ADD3-4F52-891C-35C9347A3215Q35237915-65A815C6-E132-41FC-BACB-0604C1BD50B2Q35263210-E248FD70-30D7-4D8C-BE09-941FC19B827BQ35461505-900B69DA-04FF-41A8-9A03-72B13DFC5876Q35598807-56BD7E4B-FD08-4BB2-BC88-3C219C1BD723
P2860
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Patterns of p53 mutations sepa ...... munohistochemical correlation.
@en
Patterns of p53 mutations sepa ...... munohistochemical correlation.
@nl
type
label
Patterns of p53 mutations sepa ...... munohistochemical correlation.
@en
Patterns of p53 mutations sepa ...... munohistochemical correlation.
@nl
prefLabel
Patterns of p53 mutations sepa ...... munohistochemical correlation.
@en
Patterns of p53 mutations sepa ...... munohistochemical correlation.
@nl
P2093
P1476
Patterns of p53 mutations sepa ...... munohistochemical correlation.
@en
P2093
Arndt Hartmann
Deng-Fan Cao
Gad Singer
Ie-Ming Shih
Leslie Cope
Reiko Dehari
Robert J Kurman
Robert Stöhr
Tian-Li Wang
P304
P356
10.1097/01.PAS.0000146025.91953.8D
P407
P577
2005-02-01T00:00:00Z